| 摘要 |
Compounds of formula (I)
where L, X, Y and Z are as defined in the claims, are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulphonamide derivatives and are useful in pharmaceutical compositions and methods for the treatment of CCR9-mediated diseases. |
